Sedor’s Sesquient Receives the US FDA’s Approval for Status Epilepticus
- The US FDA has approved Sesquient (fosphenytoin sodium for injection) for the treatment of status epilepticus in adult and pediatric patients
- Sedor is actively in discussions to license the rights to Sesquient for NA, EU, and other territories, except for the People’s Republic of China, where it has already been licensed
- Sesquient is the first and only FDA-approved room temperature stable fosphenytoin and can help HCPs to treat status epilepticus patients and reduce hospital costs associated with this condition
Click here to read full press release/ article | Ref: BusinessWire | Image: Twitter